Comparison of Triglyceride-Glucose Index and Atherogenic Indices Between Patients With Lipedema and Obese Controls

NCT07240298 | Completed

• 1 other identifier: istftreah1
• Study Type: observational
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

Women aged 18-75 years with a clinical diagnosis of lipedema and an obese control group will be included in the study. Sociodemographic and clinical data (age, height, weight, medications, etc.) of the participants will be recorded. For laboratory evaluation, fasting blood test results obtained within the last three months (including fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides) will be used. Based on these parameters, metabolic and atherogenic risk indicators such as the Triglyceride-Glucose Index (TyG), TyG-BMI, Atherogenic Index of Plasma (AIP), Atherogenic Coefficient (AC), Castelli Risk Index I (CRI-I), and Castelli Risk Index II (CRI-II) will be calculated. No additional biochemical tests will be collected from participants; analyses will be performed using existing laboratory results.

Conditions

Lipedema

Outcome Measures

Primary Outcomes (1)

• Triglyceride-Glucose Index (TyG):

  The TyG index will be calculated as ln \[fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2\]. It serves as a surrogate marker for insulin resistance. Higher values indicate greater metabolic risk.

  Baseline

Secondary Outcomes (5)

• TyG-BMI

  Baseline

• Atherogenic Index of Plasma (AIP):

  Baseline

• Atherogenic Coefficient (AC):

  Baseline

• Castelli Risk Index I (CRI-I):

  Baseline

• Castelli Risk Index II (CRI-II):

  Baseline

Study Arms (2)

Lipedema group

Obese patients with lipedema

Other: No intervention

Control group

Obese patients without lipedema

Other: No intervention

Interventions

No intervention OTHER

No intervention

Control group; Lipedema group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

obese patients with and without lipedema

You may qualify if:

• Clinically diagnosed with lipedema
• Obese control group with BMI ≥30 kg/m² who do not meet lipedema criteria
• Aged between 18 and 75 years
• Availability of fasting lipid profile and fasting glucose tests within the past 3 months
• Provided voluntary informed consent

You may not qualify if:

• Use of medications that routinely affect lipid or glucose metabolism: statins, fibrates, niacin, ezetimibe, high-dose omega-3 supplements, GLP-1 receptor agonists, SGLT2 inhibitors, or systemic corticosteroids (regular use within the past 3 months)
• Presence of rheumatologic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or active malignancy
• Neurological disorders (e.g., polyneuropathy, multiple sclerosis, history of stroke)
• Pregnancy or lactation
• History of lower extremity surgery or major trauma within the past 6 months
• Received injection therapy or physical therapy for the lower extremities within the past 6 months
• Active infection or dermatological disease affecting the lower extremities
• History of significant venous insufficiency or acute deep vein thrombosis (DVT)
• Alcohol or substance abuse
• Smoking

Sponsors & Collaborators

• Istanbul Physical Medicine Rehabilitation Training and Research Hospital: lead

Study Sites (1)

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Lipedema

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: November 16, 2025
• First Posted: November 20, 2025
• Study Start: October 10, 2025
• Primary Completion: November 10, 2025
• Study Completion: November 10, 2025
• Last Updated: November 20, 2025

Record last verified: 2025-11

Locations

TU (1)